Two emerging anticoagulants look set to finally make significant in-roads into clinical practice in areas that have long been dominated by warfarin and enoxaparin.
Rivaroxaban is an oral agent that competitively and reversibly inhibits activated Factor Xa. Dabigatran is a competitive reversible antagonist of thrombin. While both appear to offer potential advantages over the current commonly-used anticoagulants such as warfarin and enoxoparin, the efficacy of the two drugs in relation to each other has not yet been tested.
A joint initiative of the Patient Services Section and the Drug and Therapeutics Information Service of the Pharmacy Department, Repatriation General Hospital, Daw Park, South Australia. The RGH Pharmacy E-Bulletin is distributed in electronic format on a weekly basis, and aims to present concise, factual information on issues of current interest in therapeutics, drug safety and cost-effective use of medications.
Editor: Assoc. Prof. Chris Alderman, University of South Australia – Director of Pharmacy, RGH © Pharmacy Department, Repatriation General Hospital, Daw Park, South Australia 5041.
{ 0 comments }
